Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial

Objectives.  The objective of this study was to examine the effects of treatment with atorvastatin, α‐tocopherol and the combination of both, on lipoproteins and oxidative stress in dialysis patients.

[1]  K. Shimoi,et al.  Pro-oxidative effect of alpha-tocopherol in the oxidation of LDL isolated from co-antioxidant-depleted non-diabetic hemodialysis patients. , 2004, Atherosclerosis.

[2]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[3]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[4]  Po-Shan Wang,et al.  Selective Hypoperfusion of Anterior Cingulate Gyrus in Depressed AD Patients: A Brain SPECT Finding by Statistical Parametric Mapping , 2003, Dementia and Geriatric Cognitive Disorders.

[5]  G. Asmus,et al.  Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. , 2003, Journal of the American Society of Nephrology : JASN.

[6]  E. Topol,et al.  Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials , 2003, The Lancet.

[7]  O. Samuelsson,et al.  Dialysis modalities and dyslipidemia. , 2003, Kidney international. Supplement.

[8]  L. V. van Tits,et al.  Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. , 2003, Journal of nephrology.

[9]  H. Lakka,et al.  Six-Year Effect of Combined Vitamin C and E Supplementation on Atherosclerotic Progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study , 2003, Circulation.

[10]  M. Trip,et al.  Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. , 2002, Atherosclerosis.

[11]  D. Heymann,et al.  Deadly comrades: war and infectious diseases , 2002, The Lancet.

[12]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[13]  R. Collins,et al.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[14]  Tw.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002, The Lancet.

[15]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[16]  D. Wheeler,et al.  A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. , 2002, Kidney international.

[17]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[18]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[19]  B. Kestenbaum,et al.  HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.

[20]  M. Inaba,et al.  Atherogenic lipoproteins in end-stage renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  M. Boaz,et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.

[22]  C. Packard,et al.  Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  L. V. van Tits,et al.  alpha-tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals. , 2000, The American journal of clinical nutrition.

[24]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[25]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[26]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[27]  T. Shoji,et al.  Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.

[28]  P. Demacker,et al.  The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[29]  M. Brown,et al.  A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .

[30]  P. Demacker,et al.  Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. , 1992, Clinical chemistry.